StockDuty ← Dashboard Aug 12, 2026 11:40 PM ET
SignalFDA/Bio

DEFINIUM THERAPEUTICS, INC. (DFTX) DISCUSSES PHASE 3 VOYAGE STUDY TOPLINE RESULTS FOR DT120 IN GENERALIZED ANXIETY DISORDER TRANSCRIPT - SEEKINGALPHA

Phase 3 topline results for DT120 in anxiety disorder present key catalyst.

What changed
Why it matters
Phase 3 topline results for DT120 in anxiety disorder present key catalyst.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →